📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 19:38
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Pharmaids Pharmaceuticals Approves Q1 FY27 Results; TTM Revenue at Rs 28 Cr
Pharmaids Pharmaceuticals has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently loss-making, with a TTM net profit of Rs -12 Cr and an operating profit margin of -48.6%. Investors should note the company's strategic shift toward the Contract Research, Development and Manufacturing Organization (CRDMO) segment to offset pricing pressures in generics. The board also approved the notice for the 37th Annual General Meeting (AGM) to be held via video conferencing.
Confidence: HIGH
What changedThe company has completed its board-level review and approval of financial performance for the first quarter of FY27.
Why it mattersFor a small-cap company with a negative ROCE of -19%, quarterly results are vital to track the path toward break-even and the success of its R&D-led CRDMO strategy.
TTM Revenue: Rs 28 CrTTM Net Profit: Rs -12 CrMarket Cap: Rs 119 CrDebt-to-Equity Ratio: 0.49Promoter Holding: 32.99%
📅 Short termThe stock may see volatility as the market digests the specific revenue and loss figures for Q1 FY27 relative to the previous quarter's Rs 7.18 Cr revenue.
📈 Long termStructural recovery depends on the company's ability to scale its CRDMO services and high-value molecules to overcome generic pricing pressures.
⚠ Risk flags
- Persistent operational losses
- Negative ROCE (-19%)
- Pricing pressure from generic competitors
- Relatively low promoter holding (33%)
Key Highlights
Board approved unaudited financial results for the quarter ended June 30, 2026, on August 12, 2026.
Company reported a TTM revenue of Rs 28 Cr against a market capitalization of Rs 119 Cr.
TTM net loss stands at Rs 12 Cr, reflecting ongoing operational challenges in the generic space.
Promoter holding remains stable at 32.99% as of the June 2026 quarter.
Notice for the 37th Annual General Meeting (AGM) was approved by the board.
👀 What to Watch
Review the detailed Q1 P&L to check if the operating profit margin (OPM) is improving from the -49% seen in FY26. Monitor the integration progress of recent acquisitions like Anugraha Chemicals and Spring Labs.
Pharmaids Pharmaceuticals Approves Q1 FY27 Results and Schedules 37th AGM
Pharmaids Pharmaceuticals approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also announced its 37th Annual General Meeting (AGM) will be conducted via video conferencing. While the specific quarterly figures were not detailed in the summary letter, the company enters this period with a TTM revenue of ₹28 Cr and a net loss of ₹12 Cr. Investors should scrutinize the full results for any improvement in the -48.6% operating margin.
Confidence: HIGH
What changedThe company has completed its internal financial review for the first quarter of the 2026-27 fiscal year and initiated the process for its annual shareholder meeting.
Why it mattersFor a micro-cap company with a ₹119 Cr market cap and significant losses, quarterly results are the primary indicator of whether its pivot to the CRDMO segment is gaining traction.
Quarter Ended: June 30, 2026TTM Revenue: ₹28 CrTTM PAT: ₹-12 CrMarket Cap: ₹119 Cr
📅 Short termThe stock price may reflect the specific Q1 performance details once the full financial tables are analyzed by the market in the coming days.
📈 Long termThe structural focus remains on the company's ability to reverse its negative ROCE of -19.0% and achieve profitability through its R&D-led CRDMO strategy.
⚠ Risk flags
- Persistent net losses (₹-12 Cr TTM)
- Highly negative operating profit margins (-48.6%)
- Pricing pressure from generic competitors
Key Highlights
Board approved unaudited financial results for the quarter ended June 30, 2026
Scheduled the 37th Annual General Meeting (AGM) to be held via Video Conferencing
The board meeting concluded within 78 minutes, starting at 04:57 P.M. and ending at 06:15 P.M.
Statutory Auditors M/s PPKG & Co issued a Limited Review Report on the results
👀 What to Watch
Review the detailed Q1 FY27 financial statement to check if the recent acquisitions (Adita Bio Sys, Siri Lab, etc.) are contributing to revenue growth beyond the TTM ₹28 Cr level.
